They don't give timelines. And we don't know how good the data is except that they can take the next step - to change the primary end point. Until the end point is changed, the DSMB will not publicly weigh in on a recommendation to either continue the trial or halt due to efficacy (hope I spelt that right).
Based on timelines of other drugs currently requesting EUA, we are probably a couple / few months out yet (would love to be proven wrong on that timeline).
News 
Market Data 
Discover 
